Illumina Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina or view top-rated stocks.

9 Wall Street analysts have issued twelve-month target prices for Illumina's shares. Their ILMN stock forecasts range from $325.00 to $520.00. On average, they predict Illumina's stock price to reach $425.09 in the next twelve months. This suggests a possible upside of 128.0% from the stock's current price.
View analysts' price targets for Illumina or view top-rated stocks among Wall Street analysts.

Illumina's stock was trading at $380.44 at the beginning of the year. Since then, ILMN stock has decreased by 51.0% and is now trading at $186.43.
View the best growth stocks for 2022 here.

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Illumina.

Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Thursday, May, 5th. The life sciences company reported $1.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $0.20. The life sciences company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.22 billion. Illumina had a trailing twelve-month return on equity of 8.37% and a net margin of 15.04%. Illumina's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.89 earnings per share.
View Illumina's earnings history.

Illumina issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share guidance of $4.00-$4.20 for the period, compared to the consensus earnings per share estimate of $4.15. The company issued revenue guidance of $5.16 billion-$5.25 billion, compared to the consensus revenue estimate of $5.23 billion.

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of ILMN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (13.31%), Vanguard Group Inc. (7.91%), Edgewood Management LLC (5.56%), Loomis Sayles & Co. L P (2.25%), Polen Capital Management LLC (1.67%) and Invesco Ltd. (1.12%). Company insiders that own Illumina stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including Lansdowne Partners UK LLP, Arrowstreet Capital Limited Partnership, Parnassus Investments LLC, American Century Companies Inc., Canada Pension Plan Investment Board, Bank of Nova Scotia, Renaissance Technologies LLC, and Harding Loevner LP. Company insiders that have sold Illumina company stock in the last two years include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, and Susan H Tousi.
View insider buying and selling activity for Illumina or view top insider-selling stocks.

ILMN stock was bought by a variety of institutional investors in the last quarter, including AustralianSuper Pty Ltd, Baillie Gifford & Co., Vanguard Group Inc., Federated Hermes Inc., Sustainable Growth Advisers LP, Select Equity Group L.P., Decheng Capital Management III Cayman LLC, and Aaron Wealth Advisors LLC.
View insider buying and selling activity for Illumina or or view top insider-buying stocks.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ILMN stock can currently be purchased for approximately $186.43.

Illumina (NASDAQ:ILMN) has a market capitalization of $29.29 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or $4.599990 on an earnings per share basis.

Illumina employs 9,150 workers across the globe.

Illumina was founded in 1998.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for Illumina is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at [email protected], or via fax at 858-202-4766.